NOVN: Consensus missing large Fabhalta upside

The market continues to underestimate Fabhalta's prospects from current and potential indications. The recent positive APPULSE trial demonstrating Fabhalta's superiority by safely switching from injectable c5 to oral Fabhalta in Primary Nocturnal Haematuria (PNH) along with our unique, comprehensive analysis of Fabhalta's seven in-trial line extensions reveals multi-blockbuster opportunities with minimal competition in at least four other diseases with excellent FDA prospects...